Response to mutation and variants of the SARS-CoV-2 gene

Main Article Content



Since the COVID-19 pandemic, our society has come to understand that the cause is the Corona Virus (2019-nCoV) or more popularly known as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).  It has become a reality that as a result of the COVID-19 pandemic, many people have died. We need to record new cases of COVID-19 in other countries, namely the UK and Germany at the end of 2020. This needs to be conveyed because both countries are showing high new cases of COVID-19. The high number of new cases of COVID-19 in the UK and Germany is thought to be related with gene mutation that resulted new strain of SARS-CoV-2. It has been reported in the UK on December 2020 that SARS-CoV-2 gene mutations resulted in a new variant called VUI-202012/01 (Variant Under Investigation, year 2020, month 12, variant 01). The British government implemented new lockdowns for England and Scotland to deal with the spread of the new VUI-202012/01 variant of SARS-CoV-2. Recent news reports that the Government of Germany is extending lockdowns on its territory until January 31th 2021. The policy regarding the prohibition of foreigners entering Indonesia in relation to the emergence of a new variant of the corona virus in the UK is regulated in the Indonesia COVID-19 Task Force Circular Letter No.4 2020. Temporary entry restriction for Foreigners to Indonesia 1-14 january 2021.



Article Details

How to Cite
PARWANTO, E. (2021). Response to mutation and variants of the SARS-CoV-2 gene. Universa Medicina, 40(2), 77–78.


Zhou P, Yang X, Wang X, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579:270–3. doi: 10.1038/s41586-020-2012-7.

World Health Organization. Naming the coronavirus disease (COVID-19) and the virus that causes it. Geneva: World Health Organization; 2020

Mahase E. Covid-19: what have we learnt about the new variant in the UK? BMJ 2020;371:m4944.

Mascola JR, Graham BS, Anthony S, et al. SARS-CoV-2 viral variants-tackling a moving target. JAMA;2021:325:1261-2. doi: 10.1001/jama.2021. 2088.

Washington NL, Gangavarapu K, Zeller M, et al. Genomic epidemiology identifies emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States. medRxiv Preprint 2021. doi: 10.1101/2021.02.06.21251159 .

Galloway SE, Paul P, MacCannell DR, et al. Emergence of SARS-CoV-2 B.1.1.7 lineage — United States, December 29, 2020–January 12, 2021. Morb Mortal Wkly Rep 2021;70:95–9. DOI:

Volz E, Mishra S, Meera CM, et al. Transmission of SARS-CoV-2 lineage B.1.1.7 in England: insights from linking epidemiological and genetic data. medRxiv Preprint 2021. doi :

Villoutreix BO, Calvez V, Marcelin AG, Khatib AM. In silico investigation of the new UK (B.1.1.7) and South African (501Y.V2) SARS-CoV-2 variants with a focus at the ACE2–spike RBD interface. Int J Mol Sci 2021;22:1695.

European Centre for Disease Prevention and Control. Rapid increase of a SARS-CoV-2 variant with multiple spike protein mutations observed in the United Kingdom – 20 December 2020. ECDC: Stockholm; 2020.

Tegally H, Wilkinson E, Giovanetti M, et al. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature 2021;592:438–43.

Zhang W, Davis BD, Chen SS, et al. Emergence of a novel SARS-CoV-2 strain in southern California, USA. medRxiv preprint 2021. doi:

Xie X, LiuY, Liu J, et al. Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. Nat Med 2021;27: 620–1.

Moore JP. Approaches for optimal use of different COVID-19 vaccines: issues of viral variants and vaccine efficacy. JAMA 2021;325:1251-2. doi: 10.1001/jama.2021.3465.